Stephen O'Quinn, Pharm.D.

​

Stephen O’Quinn, Pharm.D., is the Senior Vice President, Clinical Development at Nuvie Bio.

​

Stephen has over 30 years of clinical development, medial affairs and commercialization experience involving medicines from numerous therapeutic categories and multiple indications.  Stephen was integral in the development of the market-leading triptan, sumatriptan (Imitrex  ), for the acute treatment of migraine, severing in leadership roles in support of sumatriptan for over 10 years.

​

Stephen founded Perissos, Inc, a consulting firm providing services to mid and small pharmaceutical companies after 24 years at GlaxoSmithKline.

​

Most recently, he was Vice President, Medical Affairs at Zynerba Pharmaceuticals until its acquisition by Harmony Biosciences. He was responsible for leading medical and clinical strategy in support of programs for cannabidiol transdermal gel (ZYN002) in rare/near rare neuropsychiatric disorders including Fragile X syndrome, autism spectrum disorder, and 22q.11.2 deletion syndrome.

​

Stephen obtained a Doctor of Pharmacy from the University of North Carolina at Chapel Hill where he also completed a postdoctoral fellowship in cardiovascular pharmacotherapy.